Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Jessie Villanueva; Adina Vultur; John T Lee; Rajasekharan Somasundaram; Mizuho Fukunaga-Kalabis; Angela K Cipolla; Bradley Wubbenhorst; Xiaowei Xu; Phyllis A Gimotty; Damien Kee; Ademi E Santiago-Walker; Richard Letrero; Kurt D'Andrea; Anitha Pushparajan; James E Hayden; Kimberly Dahlman Brown; Sylvie Laquerre; Grant A McArthur; Jeffrey A Sosman; Katherine L Nathanson; Meenhard Herlyn

Journal article

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Jessie Villanueva, Adina Vultur, John T Lee, Rajasekharan Somasundaram, Mizuho Fukunaga-Kalabis, Angela K Cipolla, Bradley Wubbenhorst, Xiaowei Xu, Phyllis A Gimotty, Damien Kee, Ademi E Santiago-Walker, Richard Letrero, Kurt D'Andrea, Anitha Pushparajan, James E Hayden, Kimberly Dahlman Brown, Sylvie Laquerre, Grant A McArthur, Jeffrey A Sosman, Katherine L Nathanson Show all

Cancer Cell | CELL PRESS | Published : 2010

DOI: 10.1016/j.ccr.2010.11.023

University of Melbourne Researchers

Grant McArthur Author Melbourne Medical School

Grants

Awarded by National Cancer Institute

Awarded by NATIONAL CANCER INSTITUTE

Funding Acknowledgements

We thank T. Nguyen and F. Keeney for assistance with graphics, T. Wang for help with Annexin-V analysis, and J. Kong, Y, Chen, S. Huang, M. Neri, and S. Lee for technical assistance. We thank the Microscopy and Flow Cytometry facilities at the Wistar Institute and G. Bollag for providing PLX4720. We apologize to those whose work is not mentioned here due to space constraints. This work was supported by grants from the National Cancer Institute (P01 CA114046, P01 CA025874, P30 CA010815, RO1 CA117881), the Adelson Medical Research Foundation, and GlaxoSmithKline. Sylvie Laquerre is an employee and shareholder of GlaxoSmithKline.